Clinical Trials

Breast Neoplasms

NCT05769010 2026-04-01

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

150 enrolled

Breast Neoplasms

NCT06976944 2026-02-23

PRELUDE

44 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05180006 2025-12-01

BIS-Program

33 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

454 enrolled 23 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT07065435 2025-07-15

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

74 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT02436993 2025-07-14

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

120 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

620 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06539559 2024-08-06

Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer

60 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04303988 2024-07-18

A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

35 enrolled

Breast Neoplasms

NCT03395899 2024-06-18

ECLIPSE

71 enrolled

Breast Neoplasms

NCT04408118 2024-06-04

ATRACTIB

100 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00618657 2024-02-28

Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

127 enrolled 12 charts

Breast Neoplasms

NCT00679029 2023-12-11

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

15 enrolled 9 charts

Breast Neoplasms

NCT03961698 2023-08-14

MARIO-3

91 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT00608972 2023-02-08

Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

31 enrolled 11 charts

Breast Neoplasms

NCT00773695 2023-01-09

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

150 enrolled

Breast Neoplasms

NCT00530868 2022-10-21

Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer

75 enrolled 9 charts

Breast Neoplasms

NCT05357417 2022-09-16

Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases

100 enrolled

Breast Neoplasms

NCT01989780 2022-08-04

BOOSTER

160 enrolled

Breast Neoplasms

NCT04389073 2022-02-25

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

138 enrolled

Breast Neoplasms

NCT00925652 2022-01-19

ABCDE

55 enrolled 11 charts

Breast Neoplasms

NCT00405938 2021-11-18

Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer

79 enrolled 7 charts

Breast Neoplasms

NCT00444535 2021-10-25

Lapatinib and Bevacizumab for Metastatic Breast Cancer

52 enrolled 13 charts

Breast Neoplasms, Osteitis Deformans

NCT00464646 2021-10-25

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

105 enrolled 17 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00580333 2021-05-26

Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer

51 enrolled 7 charts

Breast Neoplasms

NCT00546156 2021-05-18

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

104 enrolled 7 charts

Breast Neoplasms

NCT02185352 2021-05-07

A-Plus

120 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00723125 2021-04-29

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

60 enrolled 7 charts

Breast Neoplasms

NCT00365417 2021-04-13

Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer

45 enrolled 15 charts

Breast Neoplasms

NCT00461773 2021-03-16

Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

5 enrolled 7 charts

Breast Neoplasms

NCT00536939 2020-09-24

Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer

2 enrolled 5 charts

Breast Neoplasms

NCT00217672 2020-08-05

Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer

76 enrolled 11 charts

Breast Neoplasms

NCT00472693 2020-04-09

Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer

5 enrolled

Breast Neoplasms

NCT00394082 2019-11-25

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

50 enrolled 17 charts

Breast Neoplasms

NCT00394251 2019-11-25

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

197 enrolled 23 charts

Breast Neoplasms

NCT00281528 2019-11-22

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

208 enrolled 23 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00240071 2019-10-30

Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.

30 enrolled 7 charts

Breast Neoplasms

NCT00820547 2019-10-22

Beverly1

100 enrolled

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00083031 2019-05-21

Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer

57 enrolled

Breast Neoplasms

NCT00462865 2019-04-09

Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse

18 enrolled 8 charts

Breast Neoplasms

NCT00979641 2019-03-28

AINO

65 enrolled

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01959490 2019-03-05

Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

16 enrolled 8 charts

Breast Neoplasms

NCT00254592 2019-02-28

Neoadjuvant Treatment of Breast Cancer

43 enrolled 7 charts

Breast Neoplasms

NCT01722968 2019-02-27

BEVPAC

33 enrolled

Breast Neoplasms

NCT00403130 2019-02-20

Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer

31 enrolled 11 charts

Breast Neoplasms

NCT01004172 2018-12-14

Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases

38 enrolled 12 charts

Breast Neoplasms

NCT00733408 2018-12-04

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

59 enrolled 14 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01190345 2018-08-13

AVASTEM

75 enrolled